LYELL IMMUNOPHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
LYELL IMMUNOPHARMA INC. - More news...
LYELL IMMUNOPHARMA INC. - More news...
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
- Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
- Lyell Immunopharma Completes Acquisition of ImmPACT Bio
- Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
- Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
- Lyell Immunopharma Announces Participation in September Investor Conferences
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
- Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
- Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
- Lyell Immunopharma Announces Participation in March Investor Conferences
- Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
- Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
- Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
- Lyell Immunopharma to Participate in Upcoming Investor Conferences
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
- Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
- Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
- Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
- Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
